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Summary The usefulness of pharmacokinetically guided individualisation ofdrug therapy will depend, among
other things, on the quality of the analytical and pharmacokinetic methods used. We surveyed the quality of
analytical and pharmacokinetics methodology and reporting in a literature search of the oncology literature
from 1987 to 1992, using the Medline database. Thirty articles that examined relationships between normal
tissue toxicity and area under the plasma concentration-time curve (AUC) formed the study sample.
Analytical procedures were adequately described in 77% of the articles, but details of validation of the assay
were seriously deficient in the great majority of articles. Methods for calculation of AUC were also deficient in
over half of the articles. The findings suggest that greater attention needs to be paid to the quality of
pharmacokinetic investigation in oncology, otherwise progress in the use of pharmacokinetically guided
individualisation of dosage may be hindered.
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In recent years there has been a rapidly growing awareness in
oncology of the potential of pharmacologically guided dose
adaptation in optimising the use of anti-cancer drugs
(Liliemark and Peterson, 1991; Evans, 1993; Lonning, 1993;
Weitman et al., 1993; Workman and Graham, 1994). The use
of pharmacokinetic principles to individualise drug therapy
outside oncology has been accepted practice for many years
(Sjoqvist et al., 1980). Complex intracellular events, complex
mechanism of action of cytotoxics and drug resistance have
been suggested as reducing any possible role of phar-
macokinetic dose optimisation in oncology (Liliemark and
Peterson, 1991). Nevertheless, there is now firm evidence that
area under the plasma drug concentration-time curve or the
time during which plasma drug concentrations are main-
tained above a minimum effective concentration correlates
well with normal tissue toxicity and probably also with
tumour response (Hande, 1993; Desoize and Robert, 1994;
Newell, 1994). As a result, there is an increasing need for
further pharmacokinetically guided dosing studies to improve
individualisation of drug therapy (Liliemark and Peterson,
1991; Egorin, 1992).
The importance of using good clinical trial design and
methodology in oncology has been emphasised (DerSimonian
et al., 1982; Bliss et al., 1991) and guidelines for good clinical
research practice are well accepted. The quality of phar-
macological investigation has received much less attention in
oncology, even though there is often a potentially large mar-
gin for error in the quantitation of extremely low drug
concentrations and in the computation of pharmacokinetic
parameters (Hirtz, 1986; Graves et al., 1989). Progress in
determining the place of pharmacological principles in indi-
vidualisation of cytotoxic drug therapy will very much
depend on the quality of the analytical and pharmacokinetic
methods used. Progress in the area of pharmacokinetically
guided dosing has already been accomplished for methotrex-
ate (Evans et al., 1986) and carboplatin (Calvert et al., 1989).
In this paper we have surveyed the quality of analytical
and pharmacokinetic methodology and reporting in a sample
of recent papers from the oncology literature in which rela-
tionships between pharmacokinetics and normal tissue tox-
icity were investigated.
Methods
Articles indexed under the Medline subject heading
'antineoplastic agents' and the subheading 'pharmacokinetics'
were retrieved for the years 1987 to 1992 inclusive. Excluded
were articles not published in English, studies in animals or
in vitro, studies that used non-parenteral routes of drug
administration and studies that used hormone therapies.
From this pool, articles identified by the keywords 'correla-
tion', 'area under the curve' and 'toxicity' were selected for
review. This yielded 30 articles produced by 23 separate
research groups.
We then surveyed these 30 articles to determine how fre-
quently certain aspects of relevant study details, analytical
procedures and pharmacokinetic calculations were reported.
We also examined the quality of the analytical and phar-
macokinetic methodology reported. Criteria for assessment of
analytical reporting included the adequacy of the description
of the sample preparation and instrumentation (e.g. by high-
performance liquid chromatography, radioimmunoassay, etc.),
and the adequacy of the validation of the method in terms
of the properties of the standard curve, accuracy and
precision, sensitivity, specificity, recovery, quality control
standards and stability of the drug in plasma before
analysis (Pachla et al., 1986; Aarons et al., 1987; Shah et
al., 1992). Specific guidelines have been published by Shah
et al. (1992), and these are summarised in Table I. These
guidelines were produced from a conference on analytical
methods validation in pharmacokinetics, sponsored by the
American Association of Pharmaceutical Scientists, the US
Food and Drug Administration, Federation Internationale
Pharmaceutique, Health Protection Branch (Canada), and
the Association of Official Analytical Chemists. Phar-
macokinetic methodology was assessed according to estab-
lished criteria (Gibaldi and Perrier, 1982), with particular
reference being paid to calculation of area under the plasma
concentration vs time curve.
Results
Table II summarises the percentages of articles reporting
patient details that were considered most relevant to a study
of pharmacokinetics in cancer patients. Subject age, sex,
renal and liver function were reported in only three-quarters
of the articles examined.
Table III summarises the frequency of reporting of
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Table I Guidelines for reporting and validation of analytical methods
* Presentation of a specific. detailed description and protocol of the method
* Investigation ofextent to which environmental matrix, material or procedural vanrables
may affect the assay
* Assessment ofstability ofthe analyte in the matrix during the collection process and the
sample storage period
* Validation of the method for the intended use. employing an acceptable protocol. as
follows:
* a standard curve of 5-8 points covenrng the range of expected concentrations
* the simplest relationships for response vs concentration in the standard curve and the
fit statistically tested
* the specificty of the assay established using six independent sources of the same
matrix
* accuracy and precision by replicate (n = 5) analysis ofknown high, intermediate and
low [near lower limit of quantitation (LOQ)] concentrations. Mean value should be
within ± 15% ofthe actual value except at LOQ, where it should be within ± 20%.
Precision around the mean value should not exceed 15% coefficient ofvariation (CV).
except for LOQ, where it should not exceed 20% CV.
* Establishment of system suitability, i.e. a specific procedure to assure the optimum
operation of the system for each run
* Use ofduplicate quality control standards in each run, ofknown high. intermediate and
low (near LOQ) concentration to provide the basis for accepting or rejecting each run
* Establishment of criteria for performing repeat analysis of individual aberrant values
Table n Frequency of reporting of relevant patient details
Item Frequency (%








Table II Frequency of reporting of analytical details
Item Frequency (%
Description of sample preparation 77
and instrumentation
Validation of analytical method






Quality control samples 13
Stability in plasma 13
analytical details. The sample preparation procedure and
instrumentation details were adequately described in 77% of
the studies. Of these, 13% accomplished this by referring to
one of their own previously published papers and 10% refer-
red to the work of others. Details of the validation of the
analytical method were lacking in the majority of studies
(Table III). Twenty-three per cent of the studies provided no
validation data whatsoever, and a further 23% merely refer-
red to an earlier study from their own laboratory. Sensitivity
was the most frequently reported parameter (Table III), but
in all but one study this was reported as a detection limit
rather than as a limit of quantitation. In most cases the
method of assigning the detection limit was not stated.
Details of reporting of the calculation of AUC. the prin-
cipal pharmacokinetic parameter of interest in these studies,
are shown in Table IV. Sufficient details of how AUC was
calculated were present in 83% of the studies. The majority
of articles used the trapezoidal rule to calculate AUC, but
only 67% of these extrapolated this AUC to infinite time by
using the rate constant for the elimination phase (Table IV).
The other main deficiencies were failure to measure plasma
concentrations for a period of at least three elimination drug
half-lives and failure to incorporate the portion of AUC
Table IV Details of AUC calculation
Item Frequency (00
Calculation by trapezoidal rule 70
Extrapolation to infinity 67a
Incorporation of infusion duration 64'
Data collected > 3 drug half-lives 52a
Calculation by polyexponential 13
curve fitting
Incorporation of infusion duration 33a
Data collected > 3 drug half-lives 50a
Insufficient information to assess 17
calculation method
'Per cent ofarticles in which this was relevant.
during drug infusion (Table IV). Nevertheless, a positive
correlation between AUC and toxicity was reported in 82%
of papers.
Discwsss
Our initial literature search revealed 1396 papers published
between the years 1987 and 1992 inclusive on some aspect of
pharmacokinetics in cancer management, indicating interest
in this area. We focused on the 30 articles that examined
whether there was a high correlation between normal tissue
toxicity and AUC. We found serious deficiencies in the
reporting and methodology in the majority of the 30 articles
in aspects relevant to pharmacokinetics.
Fundamental to the reliability of derived pharmacokinetic
parameters is the quality of the analytical procedure for
determining the drug concentration in plasma. Guidelines for
drug analysis have been available for many years (Taylor.
1983; Pachla et al., 1986; Aarons et al., 1987; Shah et al.,
1992). In most of the articles reviewed in the present study
there was not enough information to assess the quality of the
assay (Table III). The main omissions were in the provision
of validation data, which allow assessment of the assay per-
formance in the hands of the investigators. It is not con-
sidered adequate to rely on validation data from other
laboratories or to use validation data obtained in the same
laboratory but at a different time, possibly by different per-
sonnel and with different equipment (Pachla et al.. 1986:
Shah et al.. 1992). Assay sensitivity is very often crucial to
the accurate determination of AUC. especially in the ext-
rapolation of AUC to infinite time. However, most studies
that addressed sensitivity failed to distinguish between the
limit of detection, defined for example according to aQwk of wiiacoldnebc presearch in oncology M J Siderov et al
nominated signal-to-noise ratio. and the limit of quantitation.
The limit of quantitation is defined as the lowest concentra-
tion on the standard curve which can be measured with
acceptable (i.e coefficient of variation within 20%) accuracy.
precision and variability (Pachla et al.. 1986; Aarons et al.,
1987: Shah et al.. 1992). Assay specificity was rarely men-
tioned in the articles reviewed (Table III). even though many
of the patients studied may have been receiving concomitant
medication that could potentially interfere with the analysis
of the drug in question. Stability of the analyte in plasma
before analysis also received little attention. Cytotoxic agents
tend to be chemically labile so that assurance of stability
during storage and processing should be a high priority with
these drugs. It is also important to include a number of
quality control standards or 'seeded controls' in each
analytical run to provide the basis for accepting or rejecting
the run (Pachla et al.. 1986: Shah et al.. 1992). but this
practice was used in only 13% of the studies (Table III).
If drug toxicity is to be related to AUC, the total AUC.
i.e. from the beginning of drug administration to infinite
time, should be used because this is the best indication of
total drug exposure to the patient. Therefore, if the drug is
given by even a short intravenous infusion, the area under
this portion of the plasma concentration-time curve should
be incorporated into the total AUC. This was not done in a
large proportion of the studies reviewed (Table IV). For
drugs with a very rapid rate of redistribution, such as
anthracyclines. curve fitting the decay of post-infusion
plasma drug concentrations can significantly underestimate
the total AUC. It is important to adjust the coefficients of
the polyexponential equation to incorporate the effect of the
infusion (Gibaldi and Perrier. 1982). Curve fitting automatic-
ally extrapolates AUC to infinite time, but calculation of
AUC by the trapezoidal method does not. However, in only
67% of articles that used the trapezoidal rule method was
AUC extrapolated beyond the last measured plasma concent-
ration to infinite time using the elimination half-life of the
drug (Table IV). Moreover, for accurate extrapolation to
infinity by the curve-fitting method and the trapezoidal rule
method, the elimination half-life should be accurately est-
imated by ensuring that the duration of plasma collection
extends for at least three drug half-lives (Gibaldi and Perrier.
1982). This was not done in half of the studies surveyed
(Table IV).
There were also deficiencies in reporting of relevant patient
details such as age. sex. and renal and hepatic function
(Table IL). These factors could potentially alter the relation-
ships between toxicity and AUC via. for example. alterations
in plasma protein binding of drug or a change in the relative
contribution to toxicity of active drug metabolites.
In addition to the sources of error already discussed. errors
could also arise in drug administration. e.g. in injection
preparation. infusion pump performance and duration of
infusion, in the timing of blood sample collection and blood
sample processing and handling before analysis and in the
collection of pharmacodynamic data. e.g. haematological
measurements. While it was not possible to assess the quality
of these procedures in the present study. they also can greatly
affect the overall quality of a pharmacokinetic-pharm-
acodynamic investigation when not adequately controlled
and validated.
In conclusion. the present study has highlighted serious
deficiencies in a sample of publications investigating the rela-
tionship between normal tissue toxicity and AUC of
cytotoxic drugs. Although. the attempt to correlate effect
with cytotoxic plasma concentration has been considered by
some to be unrewarding because complex biological pro-
cesses might obscure any possible correlations. recent liter-
ature demonstrates that basic pharmacokinetic principles
apply to the administration of many cytotoxic drugs. For
example. the study of Calvert et al. (1989) has had a major
impact on the method of dosing of carboplatin in clinical
practice. and the studies of Evans (1993) and Gianni et al.
(1990) have demonstrated that a targeted pharmacokinetic
approach to the administration of cytotoxics is possible. The
findings of the survey in the present study suggest that more
attention needs to be paid to the quality of pharmacokinetic
investigations in oncology for optimal application of phar-
macokinetically guided individualisation of cytotoxic drug
dosage in the treatment of cancer.
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